Shipra Malik, Brenda Asmara, Zoe Moscato, Jatinder Kaur Mukker and Raman Bahal* Pages 1 - 11 ( 11 )
Background: Peptide nucleic acids (PNAs) belong to the next generation of synthetic nucleic acid analogues. Their high binding affinity and specificity towards the target DNA or RNA makes them the reagent of choice for gene therapy-based applications.
Objective: To review important gene therapy based applications of regular and chemically modified peptide nucleic acids in combination with nanotechnology
Method: Selective research of the literature.
Results: However, poor intracellular delivery of PNAs have been a significant challenge. Among several delivery strategies explored till date, nanotechnology-based strategies hold immense potential. Recent studies have shown that advances in nanotechnology can be used to broaden the range of therapeutic applications of PNAs. In this review significant advances made in nanoparticle-based on PLGA polymer, silicon, oxidized carbon and graphene oxide for delivery of PNAs have been discussed.
Conclusion: Nanoparticles delivered PNAs can be implied into diverse gene therapy based applications including gene editing as well as gene targeting (antisense) based strategies.
PLGA, peptide nucleic acid, silicon, nanoparticles, γPNA, microRNA, cancer
Department of Pharmaceutical Sciences, University of Connecticut, Storrs, CT, Department of Pharmaceutical Sciences, University of Connecticut, Storrs, CT, Biomedical engineering department, University of Connecticut, Storrs, CT, Translational Medicine & Clinical Pharmacology, Boehringer-Ingelheim Pharmaceutical, Inc. Ridgefield, CT , Department of Pharmaceutical Sciences, University of Connecticut, Storrs, CT